Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC: Preoperative Therapy for Intrahepatic Cholangiocarcinoma
NCT07639528Phase 2Not yet recruiting
- Sponsor
- Northwestern University
- Start
- Dec 2027
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of futibatinib and durvalumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Northwestern University. Primary endpoints: Completion of all preoperative testing and therapy up to 3 years and Incidence of Treatment-Emergent Adverse Events up to 3 years. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
futibatinibdurvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07639528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639528.